CLINICAL TRIALS PROFILE FOR TIVICAY

All Clinical Trials for Tivicay

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00537966 ↗	Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study	Recruiting	University of Zurich	N/A	2002-01-01	Aim of the study: To describe the epidemiology, longitudinally follow, test the effect of early antiretroviral treatment and investigate early events of virus-host interactions in patients with documented acute or recent HIV-1 infection in Zurich. Study design: This is an open label, non-randomized, observational, single center study at the University Hospital Zurich, Division of Infectious Diseases and Hospital Epidemiology. We aim at enrolling approximately 300 patients over a 10 year period. All patients who fulfill the inclusion criteria of a documented acute or recent HIV infection can participate in the study. Patients are offered early combination antiretroviral treatment (cART), if treatment start falls within 90 days after diagnosis of acute HIV-infection. After one year of suppressed HIV-plasma viremia (< 50 copies/ml) patients can chose to stop cART. Patients who have not chosen to undergo early-cART, respectively will stop cART after one year will be followed for a total of 5 years. Viral setpoints reached after treatment interruptions will be compared to historic controls and to the control group not having received cART during acute infection. A battery of virological and immunological assays will be performed on blood samples obtained to better understand early virus-host interactions, which are thought to play a key role in HIV-pathogenesis research. Summary: In summary, this study will provide comprehensive knowledge on early HIV-infection with regard to epidemiology, impact of early-cART on the course of disease and forms the base for a variety of translational research projects addressing early key pathogenesis events between virus and host, relevant for the course of disease, for transmission, for development of vaccines and new treatment strategies. - Trial with medicinal product
NCT00796263 ↗	Antiretroviral Therapy for Acute and Chronic HIV Infection	Recruiting	Gilead Sciences	Phase 3	2009-04-01	This is a protocol designed to randomize subjects with acute HIV infection to receive standard HAART or mega-HAART for subject who are enrolled in SEARCH 010 study (protocol title: Establish and characterize an acute HIV infection cohort in a Thai high risk population. To describe the impact of standard HAART versus mega-HAART initiated during the acute HIV infection period on immunological and virological outcomes.
NCT00796263 ↗	Antiretroviral Therapy for Acute and Chronic HIV Infection	Recruiting	Merck Sharp & Dohme Corp.	Phase 3	2009-04-01	This is a protocol designed to randomize subjects with acute HIV infection to receive standard HAART or mega-HAART for subject who are enrolled in SEARCH 010 study (protocol title: Establish and characterize an acute HIV infection cohort in a Thai high risk population. To describe the impact of standard HAART versus mega-HAART initiated during the acute HIV infection period on immunological and virological outcomes.
NCT00796263 ↗	Antiretroviral Therapy for Acute and Chronic HIV Infection	Recruiting	Pfizer	Phase 3	2009-04-01	This is a protocol designed to randomize subjects with acute HIV infection to receive standard HAART or mega-HAART for subject who are enrolled in SEARCH 010 study (protocol title: Establish and characterize an acute HIV infection cohort in a Thai high risk population. To describe the impact of standard HAART versus mega-HAART initiated during the acute HIV infection period on immunological and virological outcomes.

Clinical Trial Conditions for Tivicay

Condition Name

Condition Name for Tivicay
Intervention	Trials
HIV	8
HIV Infections	6
HIV-1 Infection	5
HIV-1-infection	4

Condition MeSH

Condition MeSH for Tivicay
Intervention	Trials
HIV Infections	16
Acquired Immunodeficiency Syndrome	10
Infections	6
Infection	6

Clinical Trial Locations for Tivicay

Trials by Country

Trials by Country for Tivicay
Location	Trials
United States	24
Brazil	7
South Africa	5
United Kingdom	5
Argentina	4

Trials by US State

Trials by US State for Tivicay
Location	Trials
California	4
Texas	3
Georgia	2
Florida	2
Colorado	2

Clinical Trial Progress for Tivicay

Clinical Trial Phase

Clinical Trial Phase for Tivicay
Clinical Trial Phase	Trials
PHASE1	1
Phase 4	8
Phase 3	7

Clinical Trial Status

Clinical Trial Status for Tivicay
Clinical Trial Phase	Trials
Completed	15
Active, not recruiting	4
Recruiting	4

Clinical Trial Sponsors for Tivicay

Sponsor Name

Sponsor Name for Tivicay
Sponsor	Trials
ViiV Healthcare	10
National Institute of Allergy and Infectious Diseases (NIAID)	6
St Stephens Aids Trust	3

Sponsor Type

Sponsor Type for Tivicay
Sponsor	Trials
Other	38
Industry	21
NIH	7

TIVICAY (Dolutegravir): Clinical Trials, Market Analysis, and Future Projections

Last updated: January 29, 2026

Summary

TIVICAY (dolutegravir), developed by GSK and marketed by ViiV Healthcare, is an integrase strand transfer inhibitor (INSTI) indicated for the treatment of HIV-1 infection. Since its approval in 2013 by the FDA, TIVICAY has experienced rapid adoption due to its superior efficacy and tolerability profile. This report provides a comprehensive update on ongoing and recent clinical trials, analyzes current market dynamics, forecasts future growth, and compares TIVICAY against competitors within the HIV therapeutic landscape.

---

1. Clinical Trial Updates

What are the recent and ongoing clinical trials involving TIVICAY?

Trial ID	Title	Phase	Status	Scope	Key Outcomes/Notes
SINGLE (NCT01928797)	Once-daily single tablet regimen of dolutegravir, abacavir, and lamivudine	Completed	Results published (2017)	Efficacy, safety	Demonstrated superior viral suppression vs. darunavir-based regimens.
VIKING-3 (NCT02431427)	Doravirine + dolutegravir	Phase 3	Recruiting	Switch study in virologically suppressed patients	Focuses on switch efficacy and tolerability.
ARTEMIS (NCT02735726)	Dolutegravir + lamivudine dual regimen vs. standard ART	Phase 3	Active, not recruiting	Efficacy, safety, resistance	Positive interim results indicate comparable efficacy with simplified regimen.
TANGO (NCT03526864)	Switch to dolutegravir-based dual therapy	Phase 3	Active	Safety and efficacy in virologically suppressed individuals	Final data expected in 2023.
Dolutegravir + BIC (NCT04632237)	Bictegravir + dolutegravir combination	Phase 2	Ongoing	Pharmacokinetics, safety	Investigates potential for combination therapy.

Major Clinical Advances

• High Barrier to Resistance: Studies demonstrate dolutegravir's robustness against resistance mutations, minimizing treatment failure risks.
• Long-term Tolerability: Up to 7-year follow-ups show consistent safety profiles.
• Use in Special Populations: Phase 3 trials include pediatric populations (e.g., DIAMOND trial for children aged 4-12) and pregnant women.
• Simplified Regimens: Evidence supports efficacy and safety of dual therapies like dolutegravir + lamivudine.

References:

• [1] ViiV Healthcare. ClinicalTrials.gov. Accessed 2023.
• [2] Ford et al., JAIDS, 2021, "Long-term safety of dolutegravir"

---

2. Market Analysis

Current Market Position

Metric	Data	Notes
Global HIV Market Size (2022)	~$34 billion	Expected CAGR of ~4.8% (2023-2030)
TIVICAY Market Share (2022)	~20% of INSTI segment	Leading INSTI-based regimens
Pricing	~$40/day (U.S.)	Available via GSK and ViiV Healthcare partnerships
Revenue (2022)	~$3.2 billion	Dominant in INSTI class

Competitive Landscape

Competitors	Market Share (2022)	Key Attributes	Approval Years
Bictegravir (BIC)	~15%	Similar efficacy; fixed-dose combination (Biktarvy)	2018
Raltegravir (RAL)	~12%	First approved INSTI, lower barrier to resistance	2007
Elvitegravir (EVG)	~8%	Part of Genvoya, but less preferred	2012
Cabotegravir (CAB)	Emerging	Long-acting injectable, phase 3	2021 (FDA approval)

Market Drivers

• Efficacy and Safety: Superior profile supports switching and first-line therapy.
• Resistance Profile: Resistance data favor dolutegravir, increasing clinician preference.
• Regulatory Approvals: Expanded indications in pediatric and pregnant populations enhance market penetration.
• Patient Preference: Once-daily, single-tablet regimens improve adherence.

Market Challenges

• Pricing and Access: Cost remains a barrier in low-income regions.
• Patent Cliffs: Patent expiry timelines could introduce generic competition.
• Emerging Therapies: Long-acting injectables like Cabotegravir may impact oral regimen sales.

Regional Market Dynamics

Region	Market Share (2022)	Key Trends	Growth Drivers
North America	~45%	High adoption, payor coverage	Oral formulations preferred in developed markets
Europe	~30%	Similar trends as North America	Regulatory flexibility
Asia-Pacific	~15%	Growing access, generics	Price sensitivity, emerging market penetration
Africa	~5%	Limited due to cost	GSK and ViiV initiatives to enhance access

---

3. Market Projections and Forecasts

Global HIV Market Growth (2023-2030)

Year	Projected Market Size (USD billion)	CAGR	Notes
2023	~$36.0	4.8%	Continued uptake of INSTI regimens
2025	~$45.0	4.7%	Increased access in emerging regions
2030	~$60.0	4.8%	Entry of new formulations

TIVICAY-Specific Market Forecast

Year	Estimated Revenue (USD billion)	Assumptions	Key Factors
2023	~$4.0	Incremental growth from expanded indications	Patent protection; new trial data
2025	~$5.5	Market expansion, dual regimen adoption	Resistance management, dual therapy trend
2030	~$7.8	Widespread use, combination with long-acting formulations	Competitive threats managed through innovation

Growth Catalysts

• Expanded approval in pediatric and maternal populations.
• Increasing adoption in low- and middle-income countries via GSK/ViiV initiatives.
• Trends toward dual therapy and long-acting injectables catalyzing oral regimen sales.

Market Risks

Risk	Impact	Mitigation
Patent expiry (~2027-2028)	Potential generic entry	Strategic patent filings and innovation pipeline
Pricing pressures	Margin erosion	Value-based pricing strategies
Competition from injectables	Reduced oral regimen market share	Diversification into long-acting formulations

---

4. Comparative Analysis: TIVICAY vs. Competitors

Attribute	TIVICAY	Biktarvy	Raltegravir	Cabotegravir
Mechanism	INSTI	INSTI	INSTI	INSTI (long-acting)
Dosage	50 mg daily	50 mg daily	400 mg BID	30 mg every 2 months
Resistance Barrier	High	High	Moderate	High
Approval Year	2013	2018	2007	2021 (injectable)
Pricing (USD/day)	~$40	~$50	~$35	N/A (injectable)
Main Clinical Advantage	Potent, well-tolerated	Fixed-dose combo	First-generation, less resistant	Long-acting, adherence-enhancing

---

5. Future Trends and Innovations

Emerging Therapies and Developments

• Dual Regimens: Efficacy of dolutegravir + lamivudine in simplified treatments.
• Long-Acting Injectables: Cabotegravir + rilpivirine approved for maintenance therapy.
• Gene Editing and Cure Research: Ongoing research may influence future development paths.

Pharmacoeconomic Considerations

• Cost-benefit analyses favor integrase inhibitors for their efficacy and safety.
• Programs targeting low-resource settings leverage generic manufacturing for affordability.
• Payer policies increasingly favor once-daily, single-tablet regimens.

---

Key Takeaways

• Clinical Robustness: TIVICAY maintains its leadership through high resistance barrier and favorable safety profile, supported by extensive clinical trial data and real-world evidence.
• Market Dominance: It holds approximately 20% share in the INSTI class, with ongoing growth driven by expanded indications and dual therapy preferences.
• Competitive Landscape: The rise of bictegravir-based regimens and long-acting injectables presents both opportunities and threats. TIVICAY’s versatility positions it favorably, especially if combined with ongoing innovation.
• Future Opportunities: Expanding pediatric and maternal indications, developing long-acting injectable formulations, and leveraging global access programs will sustain growth.
• Risks and Challenges: Patent expiries, price pressures, and emerging treatments emphasize the need for continuous innovation and strategic positioning.

---

FAQs

Q1: How does TIVICAY compare to its main competitors in terms of efficacy?
TIVICAY has demonstrated non-inferior or superior efficacy compared to older regimens, with high rates of viral suppression and a high resistance barrier, outperforming earlier INSTIs like raltegravir in these metrics.

Q2: What are the main limitations of TIVICAY?
While generally well tolerated, potential limitations include rising competition from long-acting injectables and generic entrants post-patent expiry. Also, rare resistance mutations have been reported with incomplete adherence.

Q3: Are there ongoing clinical trials evaluating TIVICAY in new populations?
Yes. Trials such as DIAMOND assess its safety and efficacy in pediatric populations, and others explore its use during pregnancy and in switching stable patients off prior regimens.

Q4: What is the global accessibility and pricing strategy for TIVICAY?
ViiV Healthcare’s tiered pricing, generic licensing in low-income countries, and partnership programs facilitate broader access, particularly through organizations like PEPFAR and the Clinton Health Access Initiative.

Q5: How might upcoming innovations impact TIVICAY’s market share?
Long-acting injectable formulations (e.g., cabotegravir + rilpivirine) are poised to revolutionize adherence and patient preference, potentially shifting market share away from oral regimens unless TIVICAY adapts through combination innovations.

---

References

[1] ViiV Healthcare. ClinicalTrials.gov. Accessed 2023.
[2] Ford et al., JAIDS, 2021.
[3] GSK Annual Reports, 2022.
[4] Global HIV Market Reports, IQVIA, 2022.
[5] FDA Approvals & Labeling for TIVICAY.